Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spinal injection aims to slow ALS in early trial

NCT ID NCT07674667

Recruiting now Disease control Sponsor: Trace Neuroscience, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Aug 06, 2026 · Updated 7 times

Summary

This study tests a single injection of TRCN-1023 into the spinal fluid of adults with ALS. The goal is to see if it is safe and shows early signs of slowing the disease over 24 weeks. Participants are randomly assigned to receive the drug or a placebo, and neither they nor their doctors know which they get.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TRCN-1023
What this could lead to
If successful, this could point toward a new treatment that slows or stops the progression of ALS.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to all ALS patients. The drug may not show benefit or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

  • TUM Klinikum Rechts der Isar

    RECRUITING

    Munich, Germany

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, 3508 GA, Netherlands

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.